Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Theseus Pharmaceuticals, Inc. (THRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.69+0.30 (+2.24%)
At close: 04:00PM EST
13.43 -0.26 (-1.90%)
After hours: 07:28PM EST
Advertisement
Full screen
Loading interactive chart...
  • PR Newswire

    Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program

    Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies, today announced key anticipated milestones for 2023 and introduced its third development program, a pan-variant tyrosine kinase inhibitor (TKI) targeting BCR-ABL for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosom

  • TipRanks

    Investing in These 2 Biotech Stocks Could Double Your Money, Says Analyst

    Let’s talk about biotech. These stocks present a unique set of attractions for investors, especially investors willing to shoulder some extra risk. To start with, biotech firms have a famously high overhead, and equally long lead-times for product development. But that is balanced by the opportunity for huge gains – sales profits, and share appreciation – when a new drug shows strongly positive clinical trial results, or receives regulatory approval for commercialization. To give an example, jus

  • Benzinga

    Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies

    Needham has initiated coverage on Theseus Pharmaceuticals Inc (NASDAQ: THRX) with a Buy rating and a price target of $22. Theseus' discovery platform incorporates its structure-guided drug design and predictive resistance assay (PRA) to develop therapies addressing resistance to existing targeted treatments. The analyst says that PRA is a refined version of the translational approach utilized by management when it was at Ariad, which Takeda Pharmaceutical Company Limited (NYSE: TAK) acquired in

Advertisement
Advertisement